• Founder’s Vision
  • ANKTIVA
  • BCG
  • Our Science
  • Careers
  • Contact
ImmunityBio
  • Patients & Caregivers
    • ANKTIVA®
    • Clinical Trials
    • Patients
    • Therapeutic Areas
      • Bladder Cancer
      • Glioblastoma
      • HIV
      • Human Papillomavirus
      • Lymphopenia
      • Lynch Syndrome
      • Non-Hodgkin Lymphoma
      • Non-Small Cell Lung Cancer
      • Ovarian Cancer
  • Healthcare Providers
    • ANKTIVA®
    • Clinical Trials
    • Trial Investigators
    • Expanded Access
  • Researchers
    • Platforms & Modalities
    • Trial Investigators
    • Cell Licensing
    • Publications
  • Our Company
    • About
    • Pipeline
    • Contact
    • Compliance & Transparency
  • News and Events
  • Investors
Select Page

AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques

May 10, 2024 | HIV

Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells

Jul 19, 2023 | HIV

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

Feb 28, 2022 | HIV

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice

Jul 23, 2021 | COVID-19

Recent Posts

  • H.C. Wainwright 27th Annual Global Investment Conference
  • ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
  • Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
  • World Conference on Lung Cancer
  • ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap